Stock Watch: Quarter-End Jockeying At Amgen And Regeneron
Skirmishes In More Than One Therapeutic Area In An Action-Packed Week
As broad stock markets finished the third quarter of 2024 on a high, two large biotech companies battled on more than one front. Despite both announcing positive news in the last week of the quarter, neither seemed to be a clear winner over that period.
